...
首页> 外文期刊>BMC Veterinary Research >Effect of administration route and dose escalation on plasma and intestinal concentrations of enrofloxacin and ciprofloxacin in broiler chickens
【24h】

Effect of administration route and dose escalation on plasma and intestinal concentrations of enrofloxacin and ciprofloxacin in broiler chickens

机译:给药途径和剂量递增对肉仔鸡恩诺沙星和环丙沙星血浆和肠道浓度的影响

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background The (mis)use of fluoroquinolones in the fowl industry has led to an alarming incidence of fluoroquinolone resistance in pathogenic as well as commensal bacteria. Next to simply reducing antimicrobial consumption, optimizing dosage regimens can be regarded as a suitable strategy to reduce antimicrobial resistance development without jeopardizing therapy efficacy and outcome. A first step in order to limit antimicrobial resistance is to assess the exposure of the intestinal microbiota to enrofloxacin after different treatment strategies. Therefore, a study was conducted in broiler chickens to assess the effect of route of administration (oral versus intramuscular) and dose escalation (10 and 50?mg/kg body weight) on plasma and intestinal concentrations of enrofloxacin and its main metabolite ciprofloxacin after treatment with enrofloxacin once daily for five consecutive days. Four different parts of the intestinal tract were sampled: ileum, cecum, colon and cloaca. A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed to quantify both analytes in plasma and intestinal content. Sample preparation prior to LC-MS/MS analysis consisted of extraction with ethyl acetate. For intestinal content samples PBS buffer was added before extraction. The supernatant was evaporated to dryness and resuspended in water prior to analysis. Results The results in plasma and intestinal content demonstrated that biotransformation of enro- to ciprofloxacin in broiler chickens is limited. In general, the intestinal microbiota in cecum and colon is exposed to significant levels of enrofloxacin after conventional treatment (21–130?μg/g). A clear increase of intestinal concentrations was demonstrated after administration of a five-fold higher dose (31–454?μg/g). After intramuscular administration, intestinal concentrations were comparable, except for the higher levels in cloaca due to the complete bioavailability and urinary excretion. Conclusions The intestinal microbiota is exposed to high levels of the antimicrobial, after oral as well as parenteral therapy. Furthermore, a dose and time dependent correlation was observed. The impact of the detected intestinal levels on resistance selection in the intestinal microbiota has to be further investigated.
机译:背景技术氟喹诺酮类在禽类工业中的(错误)使用已导致致病菌和共生细菌中对氟喹诺酮类药物产生耐药性的惊人情况。除了简单地减少抗菌药物的消耗外,优化剂量方案可以被视为减少抗菌药物耐药性发展而不损害治疗功效和结果的合适策略。限制抗菌素耐药性的第一步是评估不同治疗策略后肠微生物群对恩诺沙星的暴露程度。因此,对肉鸡进行了一项研究,以评估给药途径(口服与肌肉注射)和剂量递增(10和50?mg / kg体重)对治疗后恩诺沙星及其主要代谢产物环丙沙星的血浆和肠道浓度的影响。连续5天每天服用一次恩诺沙星。采样了肠道的四个不同部分:回肠,盲肠,结肠和泄殖腔。开发了液相色谱-串联质谱(LC-MS / MS)方法,以定量分析血浆和肠内容物中的分析物。 LC-MS / MS分析之前的样品制备包括乙酸乙酯萃取。对于肠内容物样品,在提取前添加PBS缓冲液。将上清液蒸发至干并在分析之前重悬于水中。结果血浆和肠道含量的结果表明,在肉鸡中恩诺沙特转化为环丙沙星的生物转化受到限制。通常,盲肠和结肠中的肠道菌群经过常规治疗后会暴露于显着水平的恩诺沙星(21–130?μg/ g)。给予高剂量五倍(31–454?μg/ g)后,肠道浓度明显增加。肌肉注射后,肠道的浓度是可比的,但由于完全的生物利用度和尿液排泄,泄殖腔中的肠腔浓度较高。结论口服及肠胃外治疗后,肠道菌群均暴露于高水平的抗菌剂。此外,观察到剂量和时间依赖性。检测到的肠道水平对肠道菌群抵抗力选择的影响有待进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号